Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC
NCT05798663Phase 2Active, not recruiting
- Sponsor
- Alliance Foundation Trials
- Start
- Dec 2023
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Alliance Foundation Trials. Started Dec 2023; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05798663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798663.